• Skip to primary navigation
  • Skip to content
  • Skip to footer

BarekMed

Age Defying Medicine

  • Home
  • The Program
  • Blog
  • Men
  • Women
  • Store
  • About
  • FAQ
  • Contact Us

Full Circle

11/17/2017 Leave a Comment

Testosterone Therapy May Lower Prostate Cancer Incidence

Hypogonadal men who receive testosterone replacement therapy (TRT) may have a lower incidence of prostate cancer (PCa) than those not receiving TRT, according to study findings presented at the Sexual Medicine Society of North America 18th Annual Fall Scientific Meeting in San Antonio, Texas. In addition, PCa diagnosed in TRT recipients is less severe than PCa diagnosed in men unexposed to TRT.

I have believed this for a long time, it is nice to see good studies supporting my views.

The new findings add to those from previous studies showing a protective effect of TRT against PCa. Earlier this year, Stacy Loeb, MD, of New York University, and colleagues published the results of a case-control study in the Journal of Clinical Oncology (2017;35:1430-1436) showing that men who received TRT had a decreased risk of aggressive PCa.

IT IS UNFORTUNATE THAT MOST DOCS STILL ARE AFRAID TO USE TESTOSTERONE FEARING THEY WILL CAUSE PROSTATE CANCER

Filed Under: Uncategorized

Subscribe

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

03/27/18

HRT And Womens Heart Health

Hormone Replacement Therapy May Boost Women’s Hearts Women who take hormone replacement therapy (HRT) during menopause appear to have changes in …

keep readingView Blog
barekmed-logo-sq
  • Email
  • Facebook
  • Instagram
  • Twitter
10/20/17
Okay, Call Me Smug
10/20/17
Bombshell News
09/01/17
Ho Hum!
08/16/17
You’re Kidding
07/18/17
Coffee

Subscribe

Copyright © 2023 · BarekMed Pro on Genesis Framework · WordPress · Log in

/* ----------------------------------------- */ /* View: Recent Post Footer - start */ /* ----------------------------------------- */ #footer-recent-post .button { padding: 6px 12px; width: 48%; border-radius: 2px; border: 1px solid rgba(255,255,255,0.1) !important; float: left; display: inline-block; border: none; text-align: center; margin: 15px 0 0 1%; } #footer-recent-post .button:hover { border: 1px solid rgba(255,255,255,0.2) !important; } .footer-entry-date { font-style: italic; position: absolute; font-size: 14px; top: 0; left: 0; padding: 5px; } .featured-image { position: relative; } .recent-post-cta { position: absolute; bottom: 0 !important; width: 100%; } .footer-entry-body p { margin-bottom: 0; } .footer-entry-body { position: absolute; top: 50px !important; padding: 0 10%; width: 100%; } .featured-image img { -webkit-filter: brightness(50%); -moz-filter: brightness(50%); } #footer-recent-post h4 { margin-bottom: 0; color: #fff; font-size: 28px; text-transform: none; } @media only screen and (max-width: 600px) { .footer-entry-body { position: absolute; top: 0 !important; padding: 25px 2%; width: 100%; } } /* ----------------------------------------- */ /* View: Recent Post Footer - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: Footer Recent Posts - start */ /* ----------------------------------------- */ .recent-posts-title, .recent-posts-date { display: inline-block; float: left; } .recent-posts-date { font-size: 14px; margin: 1px 8px; border: 1px solid #222; border-radius: 3px; padding: 0 3px; } #recent-posts-footer a { color: #fff; } #recent-posts-footer a:hover { color: #d3793d; } #recent-posts-footer { display: block; float: left; width: 100%; } .recent-posts-title { font-size: 24px; text-transform: none; line-height: 1; margin: 0 auto 14px; } /* ----------------------------------------- */ /* View: Footer Recent Posts - end */ /* ----------------------------------------- */